[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -6.80 -0.49% 1,388.20 1,384.00 1,384.60 1,405.80 1,383.60 1,403.40 20,139,129 16:35:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 33,754.0 6,221.0 93.9 14.8 69,841

Glaxosmithkline Share Discussion Threads

Showing 27576 to 27599 of 28550 messages
Chat Pages: Latest  1106  1105  1104  1103  1102  1101  1100  1099  1098  1097  1096  1095  Older
DateSubjectAuthorDiscuss
18/7/2021
10:40
Switzerland has reserved 3,000 doses of the GlaxoSmithKline monoclonal sotrovimab drug to treat patients infected with Covid-19. This adds to the 3,000 doses of a similar medicine, RegN-Cov 2, developed by Switzerland’s Roche and US biotech company Regeneron. Monoclonal antibodies, which are cloned in culture and injected into patients, are seen as highly promising treatments to neutralise the virus, particularly in serious cases of infection. The antibody was discovered by Swiss company Humabs BioMed. Although the sotrovimab drug has yet to be granted regulatory approval in Switzerland, trials by GlaxoSmithKline show promising results.
alphorn
17/7/2021
08:12
BBC News - UK plans biggest flu vaccine rollout this winterhttps://www.bbc.co.uk/news/health-57867955
coxsmn
16/7/2021
17:47
I Like steak and kidney pie and chips Friday nights is Chippy night
notbitcoin
16/7/2021
16:24
Looks good - Kidney drug trials are hot news at present.
netcurtains
16/7/2021
16:02
GlaxoSmithKline's Anemia Drug Met Primary Endpoint in Five Phase 3 Studies 16/07/2021 12:50pm Dow Jones News Friday 16 July 2021 GlaxoSmithKline PLC said Friday that five Phase 3 studies of a drug used to treat patients with anemia due to chronic kidney disease have met their primary efficacy endpoint. The British pharmaceutical major said the studies evaluated the efficacy and safety of the drug, named daprodustat, as part of a Phase 3 program named Ascend. As a primary endpoint, the drug demonstrated an improvement in hemoglobin levels both in patients who weren't receiving other treatments and in patients treated with another standard treatment option, the company said. GSK said daprodustat is currently only approved in Japan for patients with renal anemia and that it isn't approved in any other country. spud
spud
16/7/2021
12:14
Some good news for CKD sufferers ... no idea if it's good news for the share price I don't think EW has communicated well with the City or moved fast enough. Elliot criticism in this regard was spot on. The strategy outlined seems fairly sensible, although I wonder if more value could be released by splitting in 3, vaccines, pharma and consumer. I don't think the consumer business will survive long as a stand alone, and will have many suitors.
alex1621
16/7/2021
12:13
lovewinshatelosses: Well said. But this is a message board not a textbook. If I want to make the case for abolishing toff schools I would probably need about 1000 pages. As many of you might know I'm pretty much in favour of abolishing all bricks and mortar schools - I'm a home school fan for - See my first post of WEY Education - (a clue it was years before the last thread was created). Earliest I can find is Feb 2017 - Well before Covid: https://uk.advfn.com/cmn/fbb/thread.php3?id=40786812&from=18
netcurtains
16/7/2021
12:04
I am sorry netcurtains, but I am going to have to highlight that EW did not pull herself up from a sink estate in 'da ends'. A background as posh as they come and could not be more public school as far as I can see, which some basic internet searches will outline. Which is absolutely fine as far as I am concerned, but your post has a dig at the public school culture in the UK...but seems to overlook this fairly significant fact :) Anyway, the only way to silence the doubters is to deliver company performance that leads to a share price well north of here. We are not talking about someone who is new to the job either. I want to see this happen and do not care who is in charge to achieve this end.
lovewinshatelosses
16/7/2021
11:43
Ecoglaxo would be better. Or even better still, just Glaxo, but being led by an experienced pharma professional and not one with a career in lipstick.
pierre oreilly
16/7/2021
10:28
They should put an i in front of its name or and X at the end. The market goes crazy for that sort of stuffi-glaxoGlaxo-xAlready looks a £ more expensive
beergut
16/7/2021
09:14
Undervalued atm, Biotech is the future, wondering who the developer will be ( Tommy Clarkes?) fill your boots gla
charlie9038
16/7/2021
08:58
What I dont understand is GSK has double the NAV of AZN and miles bigger profits and turnover. But the market does not like it. What does GSK need to do to be liked? It has the profits, it has the turnover, it has the exciting possibilities thrown up by the demerger. I just dont understand why the city is so thick? I suspect its all these public school Rodneys who dont like girls. I suspect if every public school in the UK was closed down we'd be a far more successful and dynamic country. A bit like Scandinavia or Germany or one of the other non-public school powerhouses. GSK is a great company dont let the Rodneys tell you otherwise.
netcurtains
16/7/2021
08:25
I suspect new strong management would transform the Company. However, EW still has support.Baffling....spud
spud
16/7/2021
08:11
I remember when they reached £20 in 1996. The company has had terrible leadership over the years. The culture is all wrong.
chillpill
16/7/2021
08:04
Its opened really low. Blimy.
netcurtains
16/7/2021
07:58
Big project, good for the UK. GLA
charlie9038
16/7/2021
06:27
GlaxoSmithKline seeks developer to create giant biotech research centrehttps://www.thetimes.co.uk/article/82c6569c-e5a0-11eb-a821-58982b1c936d?shareToken=67ae1ee4cb471ed151797b72d081be1d
ayl30
15/7/2021
17:17
LOL.... Keep eye on ball. More old people every year needing more and more pills. GLAXO is the right company at the right time. With added bonus of being split up and possible take-overs Glaxo is 30% cheaper than AZN but has NAV TWICE that of AZN (£20b v £10b). AZN 2020 after tax profit: £2.4b GSK 2020 after tax profit £6.1b I dont want to see Glaxo getting taken over for a pittance. Dont sell out on first bid that comes.
netcurtains
15/7/2021
16:06
alex - creasing!!
essentialinvestor
15/7/2021
15:33
Emma opened her mouth today?
spoole5
15/7/2021
15:32
Chris Chillingworth great analyst work, says it how it is.
montyhedge
15/7/2021
14:34
Why dividend being cut 30% next year then again in 2023.What's the attraction a gamble on new drugs.At least we did not complain getting a nice dividend, now cut.
montyhedge
15/7/2021
14:31
Come on this is going to 1800.(that clean trader, judging by the music, is for teenagers)
netcurtains
15/7/2021
14:29
Have a look at YouTube search The Clean Trader GSK. Very interesting.
montyhedge
Chat Pages: Latest  1106  1105  1104  1103  1102  1101  1100  1099  1098  1097  1096  1095  Older
ADVFN Advertorial
Your Recent History
LSE
GSK
Glaxosmith..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210918 03:21:03